(Q37096879)

18 August 2017

1 reference

title

Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future (English)

1 reference

18 August 2017

Norio Kohno

1

1 reference

18 August 2017

publication date

29 February 2008

1 reference

International Journal of Clinical Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

13

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

18-23

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-007-0726-2

18 August 2017

exact match

0 references

cites work

The clinical course of bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0726-2

In vitro and in vivo antitumor effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0726-2

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0726-2

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0726-2

Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

21 January 2018

1 reference

12 December 2020

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

12 December 2020

Bisphosphonates for breast cancer

1 reference

12 December 2020

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

12 December 2020

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

1 reference

12 December 2020

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

12 December 2020

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

1 reference

12 December 2020

Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity

1 reference

12 December 2020

Bisphosphonates in the treatment of skeletal metastases

1 reference

12 December 2020

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

1 reference

12 December 2020

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

1 reference

12 December 2020

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

12 December 2020

The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.

1 reference

12 December 2020

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

12 December 2020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

12 December 2020

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

1 reference

12 December 2020

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

1 reference

12 December 2020

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

12 December 2020

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

1 reference

12 December 2020

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

1 reference

12 December 2020

Perspectives on the future of bisphosphonate use in breast cancer patients

1 reference

12 December 2020

Antitumor effects of bisphosphonates

1 reference

12 December 2020

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

1 reference

12 December 2020

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

1 reference

12 December 2020

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

12 December 2020

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

12 December 2020

Metastases in carcinoma; analysis of 1000 autopsied cases

1 reference

12 December 2020

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

12 December 2020

10.1007/S10147-007-0726-2

Identifiers

DOI

1 reference

18 August 2017

1 reference